Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04882150 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
102
Enrollment target

NCT04882150: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.

NCT04882150 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 102 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04882150, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
102 participants
Enrollment target

Study Summary

The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on BMS-986196 absorption will be performed.

Interventions

  • OTHER Placebo
  • DRUG BMS-986196

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2021-05-27
Est. Completion 2022-06-10
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT04882150 record still lists

NCT04882150 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04882150 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04882150 about?

NCT04882150 is a clinical study titled "A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants". The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on BMS-986196 absorption will be performed.

What is the current status of trial NCT04882150?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2021-05-27. Estimated completion is 2022-06-10.

What interventions are being tested in trial NCT04882150?

The interventions under investigation include: Placebo (OTHER), BMS-986196 (DRUG).

Who is sponsoring clinical trial NCT04882150?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04882150's enrollment target sits among peer trials

102 543rd of 2000 higher than 1,455 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04882150, the US trial registry maintained by the National Library of Medicine. NCT04882150 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.